Research study Program year 2024 Source: CMS Open Payments

A Phase 1/2, Observer-Blind, Randomized, Placebo Controlled Multi-Coun

Research payments

$1,029,779

51 payments

Through program year 2024, $1,029,779 in research payments was reported against A Phase 1/2, Observer-Blind, Randomized, Placebo Controlled Multi-Coun, across 51 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$394,256	8
2023	Research	$635,523	43

Breakdown

Who paid Research payments · program years 2023–2024

GlaxoSmithKline, LLC. $1,029,779 51 payments

Who received the money Research payments · program years 2023–2024

Johnson County Clintrials Organisation paid for research $401,577 15 payments
Biomedical Research Alliance Of New York LLC Organisation paid for research $272,481 16 payments
Emerson Clinical Research Institute Organisation paid for research $81,037 11 payments
Henry Ford Health System Organisation paid for research $74,931 1 payment
Central Texas Clinical Research LLC Organisation paid for research $74,242 1 payment
Fenway Community Health Organisation paid for research $61,761 1 payment
Central Texas Clinical Organisation paid for research $41,819 1 payment
Fenway Comm Hlth Ctr 340B Organisation paid for research $21,930 5 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

6 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.